ARBUTUS BIOPHARMA CORP (ABUS) Stock Price, Quote, News and Overview
NASDAQ:ABUS - Nasdaq - CA03879J1003 - Common Stock - Currency: USD
ABUS Quote, Performance and Key Statistics
3.42
-0.02 (-0.58%)
The current stock price of ABUS is 3.42 USD. In the past month the price increased by 2.4%. In the past year, price increased by 17.12%.
ABUS Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About ABUS
Company Profile
Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. The company is headquartered in Warminster, Pennsylvania and currently employs 73 full-time employees. The company went IPO on 2010-11-13. The firm is leveraging its virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV) infection. Its HBV product pipeline includes Imdusiran and AB-101. Imdusiran is its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic product candidate. AB-101 is an oral PD-L1 inhibitor that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for.
Company Info
ARBUTUS BIOPHARMA CORP
701 Veterans Circle
Warminster PENNSYLVANIA 18974 US
CEO: William H. Collier
Employees: 73
Company Website: https://www.arbutusbio.com/
Investor Relations: https://investor.arbutusbio.com
Phone: 16044193200
ARBUTUS BIOPHARMA CORP / ABUS FAQ
What is the stock price of ARBUTUS BIOPHARMA CORP today?
The current stock price of ABUS is 3.42 USD. The price decreased by -0.58% in the last trading session.
What is the ticker symbol for ARBUTUS BIOPHARMA CORP stock?
The exchange symbol of ARBUTUS BIOPHARMA CORP is ABUS and it is listed on the Nasdaq exchange.
On which exchange is ABUS stock listed?
ABUS stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ARBUTUS BIOPHARMA CORP stock?
11 analysts have analysed ABUS and the average price target is 5.3 USD. This implies a price increase of 55.09% is expected in the next year compared to the current price of 3.42. Check the ARBUTUS BIOPHARMA CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ARBUTUS BIOPHARMA CORP worth?
ARBUTUS BIOPHARMA CORP (ABUS) has a market capitalization of 648.06M USD. This makes ABUS a Small Cap stock.
How many employees does ARBUTUS BIOPHARMA CORP have?
ARBUTUS BIOPHARMA CORP (ABUS) currently has 73 employees.
What are the support and resistance levels for ARBUTUS BIOPHARMA CORP (ABUS) stock?
ARBUTUS BIOPHARMA CORP (ABUS) has a support level at 3.41 and a resistance level at 3.44. Check the full technical report for a detailed analysis of ABUS support and resistance levels.
Is ARBUTUS BIOPHARMA CORP (ABUS) expected to grow?
The Revenue of ARBUTUS BIOPHARMA CORP (ABUS) is expected to decline by -70.27% in the next year. Check the estimates tab for more information on the ABUS EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ARBUTUS BIOPHARMA CORP (ABUS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ABUS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ABUS, evaluating the profitability, health, valuation and growth aspects
- ARBUTUS BIOPHARMA CORP (ABUS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ARBUTUS BIOPHARMA CORP (ABUS) Sales and EPS estimates to see what analysts future expectations are.
- ARBUTUS BIOPHARMA CORP (ABUS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ARBUTUS BIOPHARMA CORP (ABUS) Insider and Institutional Ownership to learn about the owners and their transactions.
- ARBUTUS BIOPHARMA CORP (ABUS) Stock Chart to make your own analysis
- ARBUTUS BIOPHARMA CORP (ABUS) Latest news and press-releases to stay up to date.
Does ARBUTUS BIOPHARMA CORP (ABUS) stock pay dividends?
ABUS does not pay a dividend.
When does ARBUTUS BIOPHARMA CORP (ABUS) report earnings?
ARBUTUS BIOPHARMA CORP (ABUS) will report earnings on 2025-02-27, after the market close.
What is the Price/Earnings (PE) ratio of ARBUTUS BIOPHARMA CORP (ABUS)?
ARBUTUS BIOPHARMA CORP (ABUS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.42).
What is the Short Interest ratio of ARBUTUS BIOPHARMA CORP (ABUS) stock?
The outstanding short interest for ARBUTUS BIOPHARMA CORP (ABUS) is 4.56% of its float. Check the ownership tab for more information on the ABUS short interest.
ABUS Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to ABUS. When comparing the yearly performance of all stocks, ABUS is one of the better performing stocks in the market, outperforming 70.2% of all stocks.
ABUS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ABUS. While ABUS has a great health rating, there are worries on its profitability.
ABUS Financial Highlights
Over the last trailing twelve months ABUS reported a non-GAAP Earnings per Share(EPS) of -0.42. The EPS increased by 8.88% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -54.61% | ||
| ROE | -71.76% | ||
| Debt/Equity | 0 |
ABUS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to ABUS. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of 10.05% and a revenue growth -70.27% for ABUS